The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug price negotiation program under President Donald Trump's administration. The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under President Donald Trump's administration following criticism from the pharmaceutical industry for the Biden-era law.

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a median 4% at the start of this year.The modest size of the annual increases could help companies avoid criticism of gouging from President Trump while seeking his administration’s support for such priorities as taking aim at the rebates given to middlemen and altering a federal program providing discounts to certain hospitals.

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more transparent.